Hemolytic uremic syndrome : symptoms, treatment options, and prognosis [E-Book]
Series: Renal and urologic disordersPublisher: New York : Nova Biomedical, [2015]Description: 1 online resourceContent type:- text
- computer
- online resource
- 9781634632461
- 163463246X
- WH 170
Contents:
Summary: Hemolytic uremic syndrome (HUS) is characterized by the triad non-immune micro-angiopathic hemolytic anemia, thrombocytopenia and acute renal failure. The disease mainly affects children one to ten years of age. It begins after an incubation period of 4 to 7 days with abrupt onset of bloody diarrhea and abdominal pain. Two to ten days later, microangiopathy, haemolytic anaemia, thrombocytopenia, and acute renal failure develop. HUS microangiopathy can involve almost any organ, but damage to kidneys and central nervous system cause the most severe clinical problems. This book discusses the symp.
Chapter I: The Role of Thrombin in Hemolytic Uremic Syndrome and Other Thrombotic Microangiopathies; Abstract; Introduction; 1. Thrombin Activation in EndothelialCell Physiology; 2. Modulation of Thrombin in TMAs; 3. Effects of Shiga Toxin on EndothelialCells and Thrombin Production; 4. Animal Models; 5. Treatments Targeting Thrombin in HUSand TMAs.
6. Inflammation and Thrombosis:Connections and ConvergenceConclusion; References -- Chapter II: Therapeutic Apheresis in Children with Renal Diseases, Especially Hemolytic Uremic Syndrome; Abstract; Introduction; Hemolytic-Uremic Syndrome (HUS); Rapidly Progressive Glomerulonephritis (RPGN); Anti-Basement Membrane Antibody Glomerulonephritis (Goodpasture Syndrome, ABM-ab-GN); Immune Complex Nephritis (ICN); RPGN with or without Glomerular Deposition (ANCA ab) Pauci-Immune RPGN; Therapy Recommendations for RPGN; Glomerulonephritis with Nephrotic Syndrome (NS); Myoglobulinemic Renal Failure.
Acute Kidney Injury (AKI)Kidney Transplant Rejection; Summary; References -- Chapter III: The Consequences of Soliris�Therapy in Patients with aHUS; Abstract; Background; The Role of Complement in aHUS; Limitations of Supportive Care Options; Eculizumab; Treatment; Ethical Annotation; Conclusion; References -- Chapter IV: Hemolytic Uremic Syndrome: Overview and Update; Abstract; HUS is Classified Accordingto the Etiology into 3 Categories; Epidemiology; Symptoms; Extrarenal Complications; Pathogenesis; Diagnosis; Treatment Options; Prognosis; Conclusion; References; Blank Page; Index.
| Item type | Home library | Class number | URL | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|
| Electronic book | Stenhouse Library (Kingston Hospital) Online | Link to resource | Available |
Includes bibliographical references and index.
Description based on print version record.
Chapter I: The Role of Thrombin in Hemolytic Uremic Syndrome and Other Thrombotic Microangiopathies; Abstract; Introduction; 1. Thrombin Activation in EndothelialCell Physiology; 2. Modulation of Thrombin in TMAs; 3. Effects of Shiga Toxin on EndothelialCells and Thrombin Production; 4. Animal Models; 5. Treatments Targeting Thrombin in HUSand TMAs.
6. Inflammation and Thrombosis:Connections and ConvergenceConclusion; References -- Chapter II: Therapeutic Apheresis in Children with Renal Diseases, Especially Hemolytic Uremic Syndrome; Abstract; Introduction; Hemolytic-Uremic Syndrome (HUS); Rapidly Progressive Glomerulonephritis (RPGN); Anti-Basement Membrane Antibody Glomerulonephritis (Goodpasture Syndrome, ABM-ab-GN); Immune Complex Nephritis (ICN); RPGN with or without Glomerular Deposition (ANCA ab) Pauci-Immune RPGN; Therapy Recommendations for RPGN; Glomerulonephritis with Nephrotic Syndrome (NS); Myoglobulinemic Renal Failure.
Acute Kidney Injury (AKI)Kidney Transplant Rejection; Summary; References -- Chapter III: The Consequences of Soliris�Therapy in Patients with aHUS; Abstract; Background; The Role of Complement in aHUS; Limitations of Supportive Care Options; Eculizumab; Treatment; Ethical Annotation; Conclusion; References -- Chapter IV: Hemolytic Uremic Syndrome: Overview and Update; Abstract; HUS is Classified Accordingto the Etiology into 3 Categories; Epidemiology; Symptoms; Extrarenal Complications; Pathogenesis; Diagnosis; Treatment Options; Prognosis; Conclusion; References; Blank Page; Index.
Hemolytic uremic syndrome (HUS) is characterized by the triad non-immune micro-angiopathic hemolytic anemia, thrombocytopenia and acute renal failure. The disease mainly affects children one to ten years of age. It begins after an incubation period of 4 to 7 days with abrupt onset of bloody diarrhea and abdominal pain. Two to ten days later, microangiopathy, haemolytic anaemia, thrombocytopenia, and acute renal failure develop. HUS microangiopathy can involve almost any organ, but damage to kidneys and central nervous system cause the most severe clinical problems. This book discusses the symp.
Master record variable field(s) change: 050, 082
There are no comments on this title.
Log in to your account to post a comment.
London Health Libraries Consortium Privacy notice and Membership terms and conditions